“In my opinion, these results will have very little influence on how CAC is used presently for CVD risk assessment,” he said. “To my knowledge, there is presently no guideline or recommendation regarding the use of CAC progression for CVD risk assessment. This is because of the inherent challenges in assessing CAC progression and the paucity of data.”
“The ACC/AHA guidelines clearly recommend the use of CAC, not CAC progression,” Dr. Yeboah concluded. “The take away message here is that physicians should not use CAC progression for CVD risk assessment. More research is needed to fully understand CAC progression.”
SOURCE: http://bit.ly/29rOdFM and http://bit.ly/29olMIA
J Am Coll Cardiol Imag 2016.